Clinical trials: Coronary Small Vessel Disease
Ischemic Heart Disease, Microvascular Coronary Artery Disease
The Cerebral-Coronary Connection (C3) Study
This is a prospective cohort blinded study with the aim to investigate the prevalence and clinical impact of coronary microcirculatory dysfunction (CMD) in patients with ischemic heart disease, and its association with cerebral…
- Conditions
- Ischemic Heart Disease, Microvascular Coronary Artery Disease, Depression, Endothelial Dysfunction
- Trial name
- C3 (NCT04131075)
- Testing
- Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Instituto de Salud Carlos III
Coronary Artery Disease, Obesity
Structured Physiotherapy Program in Obese and Non-obese Patients
A routine physiotherapy program has been shown to be effective in the prevention and treatment of cardiopulmonary diseases. It also significantly increases functional capacity following coronary artery bypass grafting.
- Trial name
- NCT05357937
- Testing
- standard physiotherapy program
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- University of Jazan
Fabry Disease
4D-310 in Adults With Fabry Disease and Cardiac Involvement
This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration.
- Trial name
- NCT05629559
- Testing
- 4D-310
- Where
- 4 sites in Australia, Taiwan
- Volunteers
- 18 people
- Sponsor
- 4D Molecular Therapeutics
Fabry Disease, Left Ventricular Hypertrophy
Viennese Prevalence Study of Anderson-Fabry Disease
The prevalence of Anderson - Fabry disease in patients with left ventricular hypertrophy is unclear. The investigators will examine urine - α - Galactosidase activity and globotriaosylceramide isoforms in these patients.
- Trial name
- VIEPAF (NCT00871611)
- Where
- Austria
- Volunteers
- 4,000 people
- Sponsor
- Medical University of Vienna
Coronary Artery Disease (CAD)
Validity and Reliability of the 6-Minute Pegboard and Ring Test in Patients With Coronary Artery Disease
Coronary artery disease, a cardiovascular disease, causes significant mortality and morbidity. Due to the impairment of arterial blood flow in coronary artery disease, the heart muscle cannot receive an adequate blood supply…
- Trial name
- NCT07163741
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Gazi University
Coronary Artery Disease
Drug-coated Balloons Versus Drug-eluting Stents for de Novo Small-vessel Coronary Artery Disease
This prospective, multicenter observational study will compare the safety and clinical outcomes of drug-coated balloon angioplasty and second-generation drug-eluting stent implantation in patients undergoing percutaneous coronary…
- Trial name
- DCB-SVD (NCT07839806)
- Testing
- Drug coated balloon, Drug Eluting stent
- Where
- Greece
- Volunteers
- 230 people
- Sponsor
- National and Kapodistrian University of Athens
Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
First-in-Human Study Using the SiroMax™ Sirolimus-Coated Balloon Catheter as a Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter to Treat Subjects Who Have Coronary Artery Disease (CAD) Involving In-Stent Restenosis (ISR) or an Unstented Lesion in a Small Coronary Vessel (DNSV).
The goal of this clinical trial is to learn if the SiroMax™ drug-coated balloon catheter is safe and works to treat stenotic coronary lesions in adults.
- Conditions
- Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), In-Stent Restenosis or De Novo Coronary Artery Lesions, In-Stent Stenosis (Restenosis) of Coronary Artery Stent
- Trial name
- SMART-I (NCT07811024)
- Testing
- Sirolimus-coated balloon catheter
- Where
- 2 sites in Uzbekistan
- Volunteers
- 60 people
- Sponsor
- Tonic Medical, Inc.
Fabry Disease
Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy
Study Design: This is an observational study. No treatment or intervention will be assigned to the subjects. All patients will receive full standard of care concomitant medication for the treatment of their cardiac condition.
- Trial name
- NCT03230591
- Testing
- Echocardiography
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Yonsei University
Stable Angina Pectoris, Unstable Angina Pectoris
Small Coronary Artery Treated by TAXUS Liberté Registry in Japan
The utilization of paclitaxel-eluting coronary stents in small vessel diseases is effective in reducing both repeat revascularization and major adverse cardiac events within two year follow-up.
- Trial name
- SACRA (NCT00955214)
- Testing
- TAXUS Liberté paclitaxel-eluting coronary stent system
- Where
- 23 sites in Japan
- Volunteers
- 250 people
- Sponsor
- Society for Advancement of Coronary Intervention Research
Fabry Disease
Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease
Fabry disease (OMIM 301500) is an X-linked inborn error of sphingolipid metabolism resulting from the deficiency of the lysosomal enzyme alpha-galactosidase A.
- Trial name
- HEART (NCT00487630)
- Testing
- recombinant alpha-galactosidase A
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Fabry Disease, Fabry Disease, Cardiac Variant
Long-Term Follow-up of Subjects Who Were Treated With ST-920
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol.
- Trial name
- NCT05039866
- Testing
- ST-920
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 32 people
- Sponsor
- Sangamo Therapeutics
Ischemic Heart Disease, Heart Failure
SNORD3A IN ISCHEMIC HEART DISEASE AND HEART FAILURE
This is a prospective, non-randomized, single center, open label clinical study enrolling patients affected by 1) chronic ischemic heart disease with evidence or suspect significant myocardial ischemia (group 1, CCS) or 2) acute…
- Trial name
- SENSITISE (NCT06678802)
- Testing
- Blood sampling
- Where
- Italy
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Federico II University
Coronary Artery Disease
Balloon Elution and Late Loss Optimization (BELLO) Study
Prospective multicentre randomized (1:1) investigator initiated study, in which consecutive patients undergoing percutaneous revascularization of small coronary vessels will be assigned to one of the two study arms: 1.
- Trial name
- BELLO (NCT01086579)
- Testing
- IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon), Taxus (Paclitaxel eluting stent)
- Where
- Italy
- Volunteers
- 182 people
- Sponsor
- Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Coronary Small Vessel Disease
A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease
The purpose of this study is to evaluate the efficacy and safety in the treatment of Coronary Small Vessel Disease by drug coated balloon (DCB) Dissolve™ versus drug eluting stent (DES) Resolute™ Integrity.
- Trial name
- NCT03376646
- Testing
- Cohort A: Dissolve™, Cohort A: Resolute™ Integrity, Cohort B: Dissolve™-2.00mm
- Where
- 15 sites in China
- Volunteers
- 277 people
- Sponsor
- DK Medical Technology (Suzhou) Co., Ltd.
de Novo, Symptomatic Ischemic Heart Disease
BIOFLOW-SV All Comers Registry
Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm.
- Conditions
- de Novo, Symptomatic Ischemic Heart Disease, Restenoses, Coronary
- Trial name
- BIOFLOW-SV (NCT03600948)
- Testing
- Orsiro Sirolimus Eluting Coronary Stent System
- Where
- 2 sites in Brazil
- Volunteers
- 261 people
- Sponsor
- Biotronik AG
Hypertension
Bisoprolol in Hypertension: Effect on Concomitant Elevated Heart Rate
The b.p.m study will be performed to gain the insight in the courses of illness and therapy in subjects, suffering from hypertension and that have elevated heart rate.
- Trial name
- NCT01109043
- Testing
- Bisoprolol or bisoprolol + HCTZ
- Where
- Austria
- Volunteers
- 351 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Coronary Arterial Disease (CAD)
Drug-Coated Coronary Balloons in Different Clinical Scenarios
Coronary stents are the best treatment method ever accepted in the treatment of coronary artery stenoses. Due to some limitations and complications of stent use, the operators tried to find new solutions.
- Trial name
- DCB-DCS (NCT06915597)
- Where
- 5 sites in Turkey (Türkiye)
- Volunteers
- 1,500 people
- Sponsor
- Kutahya Health Sciences University
Coronary Disease, Diabetes Mellitus
Drug Eluting Balloon for Prevention of Constrictive Remodeling
Earlier studies indicated that Percutaneous coronary intervention (PCI) may be problematic in diffuse small vessel disease especially of diabetic patients.
- Trial name
- NCT01690572
- Testing
- Paclitaxel coated balloon catheter, uncoated balloon catheter "sprinter legend"
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Prof. Dr. med. Christoph Hehrlein
Fabry's Disease
Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)
The purpose of this study is to evaluate the impact of ERT on LV diastolic function and flow in patients with Fabry's cardiomyopathy using diastolic stress echocardiography, LV vortex flow and CMR.
- Trial name
- NCT02469181
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Yonsei University
Diabetes Mellitus Type 2, Hypercholesterolemia
Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes
It is of interest how ezetimibe alone or in combination with statin may influence atherogenic dense Low Density Lipoprotein (dLDL) in patients with type 2 diabetes mellitus.
- Trial name
- EZE (NCT01384058)
- Testing
- ezetimibe, simvastatin, Ezetimibe 10/Simvastatin 20
- Where
- 2 sites in Germany
- Volunteers
- 41 people
- Sponsor
- University Hospital Freiburg